Form 4: Erasca Director James Bristol Granted 120,000 Stock Options

Erasca, Inc. Director James Arthur Bristol was granted 120,000 stock options with an exercise price of $1.45, vesting fully on June 24, 2026.

Summary

• Director James Arthur Bristol of Erasca, Inc. acquired 120,000 stock options.
• The options have an exercise price of $1.45 per share.
• All 120,000 options will vest on June 24, 2026, contingent on Mr. Bristol's continuous service to the Issuer.
• The options expire on June 23, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive step for corporate governance, aligning the director's interests with long-term shareholder value, though it is a routine compensation event rather than a significant operational or financial announcement.

Positives

• The grant of stock options aligns the director's interests with long-term shareholder value.
• The vesting schedule encourages continued service and commitment from the director.

Risks

• The value of the options is subject to the future performance of Erasca's common stock.
• Vesting is contingent on continuous service, meaning the options could be forfeited if service ceases before the vesting date.

Future Outlook

The grant of stock options to Director James Arthur Bristol aligns his future financial interests with the long-term performance of Erasca, Inc.'s common stock, contingent on his continued service until the vesting date.

Industry Context

This is a standard equity compensation practice for directors in the biotechnology and pharmaceutical industry, aiming to incentivize long-term commitment and performance by aligning their interests with shareholders.

Comparison to Industry Standards

• Equity grants to directors, such as stock options, are a common form of compensation across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The specific size of the grant (120,000 options) and the exercise price ($1.45) would typically be evaluated against peer companies of similar market capitalization and stage of development, though specific comparable companies are not mentioned in this filing.

Stakeholder Impact

• Shareholders: Potential long-term benefit from aligned director interests, as the director's compensation is tied to the company's stock performance.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

Keywords

Erasca, ERAS, stock options, insider transaction, Form 4, director compensation, equity grant, beneficial ownership